340B Drug Pricing Program

340B Drug Pricing Program
Name	340B Drug Pricing Program
Established	1992
Legislation	Veterans Health Care Act of 1992
Administered by	Health Resources and Services Administration
Purpose	Reduced drug acquisition costs for eligible entities

Contents

340B Drug Pricing Program is a federal program created to allow certain safety-net providers to purchase outpatient drugs at reduced prices. It was enacted as part of the Veterans Health Care Act of 1992 and is administered by the Health Resources and Services Administration, with statutory ties to the Public Health Service Act and interactions with federal programs such as Medicaid and Medicare. The program has influenced financial operations at institutions including Johns Hopkins Hospital, Mayo Clinic, and community-based federally qualified health centers.

Overview

The 340B initiative was enacted to enable participating entities to stretch scarce resources by obtaining discounted prices from pharmaceutical manufacturers, a policy rooted in debates between lawmakers such as Senator Edward Kennedy and Representative Henry Waxman and implemented under agencies like the Department of Health and Human Services and the Health Resources and Services Administration. Over time the program has intersected with litigation involving parties including Pharmaceutical Research and Manufacturers of America and health systems such as Kaiser Permanente and Ascension Health. Major legislative and regulatory milestones involved entities like the U.S. Supreme Court, the U.S. Court of Appeals for the D.C. Circuit, and rulemaking published by the Federal Register.

Eligibility criteria define covered entities drawn from statutory categories including federally qualified health centers, Ryan White HIV/AIDS Program grantees, Critical Access Hospitals, and certain children's hospitals and disproportionate share hospitals. Qualifying organizations must register through the Health Resources and Services Administration and are identified by relationships with programs such as Medicaid managed care and service populations like those served by Indian Health Service facilities and rural health clinics. Notable covered entities range from national systems like Veterans Health Administration affiliates (in limited contexts) to local nonprofit providers such as community clinics and academic medical centers including Brigham and Women's Hospital.

Manufacturers that participate in federal drug rebate programs are required to offer 340B ceiling prices, computed in relation to statutory rebate formulas originally created for Medicaid rebate calculations and influenced by guidance from the Centers for Medicare & Medicaid Services and the Office of Inspector General (United States Department of Health and Human Services). Covered entities acquire outpatient drugs through contracts with wholesalers including McKesson Corporation, Cardinal Health, and AmerisourceBergen, and may use contract pharmacies operated by retail chains such as Walgreens, CVS Health, and regional pharmacy groups. Pricing mechanisms involve calculation of ceiling prices, adjustments for innovator drugs and biologics, and recordkeeping obligations that affect billing to payers like Blue Cross Blue Shield Association and Aetna.

The program has generated litigation and policy disputes involving stakeholders such as Pharmaceutical Research and Manufacturers of America, hospital systems like CommonSpirit Health, and federal agencies including Health Resources and Services Administration and Centers for Medicare & Medicaid Services. Key controversies include manufacturer claims about program expansion, disputes over contract pharmacy arrangements involving chains like Walgreens Boots Alliance and CVS Pharmacy, and lawsuits on topics addressed by courts including the U.S. Court of Appeals for the Federal Circuit and the U.S. District Court for the District of Columbia. Congressional committees such as the United States Senate Committee on Finance and the House Committee on Energy and Commerce have held hearings with participation by executives from Pfizer, Merck & Co., and nonprofit health systems. Policy debates have considered statutory interpretation issues linked to the Public Health Service Act and administrative rulemaking by the Health Resources and Services Administration.

Advocates including leaders from Community Catalyst, National Association of Community Health Centers, and safety-net hospitals such as Parkland Health & Hospital System argue that savings support expanded services including primary care, behavioral health, and pharmacy programs. Critics including manufacturers and some payers argue that revenues from discounts have funded hospital system expansions at organizations like HCA Healthcare and State University of New York hospitals rather than directly lowering patient out-of-pocket costs. Empirical studies by institutions such as The Commonwealth Fund, Kaiser Family Foundation, and academic centers including Harvard Medical School and University of California, San Francisco have examined associations between 340B participation and metrics like charity care, service volume, and drug pricing impacts for patients insured by Medicare Part D and private insurers like UnitedHealthcare.

Oversight mechanisms include registration and recertification through the Health Resources and Services Administration, program audits by the Office of Inspector General (United States Department of Health and Human Services), and enforcement actions coordinated with agencies such as the Centers for Medicare & Medicaid Services and congressional oversight from bodies like the Government Accountability Office. Compliance responsibilities require covered entities to maintain auditable records, prevent diversion, and ensure consistency with statutory patient definition rules; enforcement responses have ranged from guidance letters issued by HRSA to litigation involving manufacturers and health systems such as Providence Health & Services and Trinity Health. Recent rulemaking and advisory opinions have been shaped by input from stakeholders including American Hospital Association, Association of American Medical Colleges, and Health Care Service Corporation.